June 28, 2010
MagForce Nanotechnologies AG receives European regulatory approval for its Nano Cancer® therapy
Berlin - Following many years of research and development efforts, MagForce Nanotechnologies AG has received European regulatory approval for its Nano-Cancer® therapy under the provisions of the German Medical Devices Act (Medizinproduktegesetz). This approval follows successful completion of the conformity evaluation procedure of the company’s NanoTherm® magnetic fluid by Medcert GmbH and of its NanoActivator® magnetic field applicator by Berlin Cert GmbH. Both of these medical certification and testing companies are officially authorized centers for the conformity evaluation of medical devices. The regulatory approval applies to the treatment of brain tumors throughout the EU.
DISCLAIMER:
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates" or "will." Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements.
June 22, 2010
MagForce Nanotechnologies AG successfully completes share placement
Berlin - MagForce Nanotechnologies AG, a medical technology company listed in the Entry Standard segment of the Frankfurt Stock Exchange, completed a placement of equity with German and international institutional investors. A total of 80,190 newly issued shares were placed, with profit participation rights dating from January 1, 2009, at a price of EUR 42.00 per share. The gross proceeds from this capital increase of EUR 3,367,980.00 will go to the company and are to be used to finance its further growth.
This transaction increases the nominal capital of the company, until now EUR 3,773,198.00 divided into 3,773,198 shares at an imputed nominal value of EUR 1.00, by an amount of EUR 80,190.00, thus bringing its nominal capital to EUR 3,853,388.00. Subscription rights to existing shareholders were excluded by the authority under sec. 6 para. 3 of the company’s articles of incorporation (Satzung).
DISCLAIMER:
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates" or "will." Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements.
June 16, 2010
MagForce Nanotechnologies AG announces capital increase with exclusion of subscription rights
Berlin - MagForce Nanotechnologies AG, a medical technology company listed in the Entry Standard segment of the Frankfurt Stock Exchange, today announced its intention to increase its share capital under the procedure to exclude subscription rights for existing investors. The company’s nominal capital is EUR 3,773,198.00, divided into 3,773,198 common shares in bearer form with an imputed nominal value of EUR 1.00. In its resolution of the June 16, 2010, approved by the supervisory board on June 16, 2010, the executive board of MagForce Nanotechnologies has decided to increase its share capital by up to EUR 80,190 against cash contributions, bringing its approved capital limit up to EUR 3,853,388.
Up to 80,190 new common shares will be issued, with profit participation rights dating from January 1, 2009. The company has excluded subscription rights to existing shareholders by its authority under sec. 6 para. 3 of its articles of incorporation (Satzung). The new shares will be privately placed with German and international institutional investors at an offering price of EUR 42.00 per share.
The proceeds of the capital increase are to be used to finance the company’s further growth.
DISCLAIMER:
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates" or "will." Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements.
November 3, 2009
MagForce Nanotechnologies Reaches Primary Study Endpoint in Pivotal Glioblastoma Study
Berlin - MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma. The primary study endpoint, which was to extend the median survival time following tumor recurrence by three months compared to a historical control group, was significantly exceeded in the actual results. The 59 patients evaluated to determine the clinical efficacy of treatment with Nano-Cancer® therapy with accompanying radiotherapy attained a median survival time following diagnosis of the first tumor recurrence of 13.4 months* (99% confidence interval: 9.7-17.1 months). Compared to the 6.2-month median survival time* following recurrence observed in a recently published EORTC study with a total of 573 patients**, the survival time with Nano-Cancer® therapy is statistically highly significant longer (p-value < 0.01).
The results of the clinical trial will now form the basis for the conformity assessment procedure required under the German Medical Devices Act (Medizinproduktegesetz). The product file should be submitted as planned by year end to “MEDCERT Zertifizierungs- und Prüfungsgesellschaft für die Medizin GmbH”, a notified body for the certification of medical devices. Following successful completion of the conformity assessment procedure for Nano-Cancer® therapy and EC type testing of the magnetic field applicator, MagForce will be able to market its Nano-Cancer® therapy throughout the European Union.
* Determined with the Kaplan-Meier method
** Stupp et al., Lancet Oncol 2009; 10:459-66
DISCLAIMER:
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates" or "will." Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements.
September 19, 2007
MagForce Nanotechnologies to Complete Exchange Listing on September 20
Berlin – The shares of MagForce Nanotechnologies AG will be admitted for trading on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange on September 20 and simultaneously included in its "Entry Standard" segment. The company’s securities prospectus was approved by the German Financial Supervisory Authority (BaFin) on September 18, 2007 and may be viewed on the MagForce Nanotechnologies website (www.magforce.com). Steubing AG, a Frankfurt-based investment bank, is supporting Magforce as its Deutsche Börse Listing Partner, Designated Sponsor and Lead Broker. The first price setting will take place on the Frankfurt Stock Exchange on September 20, under the German securities symbol (WKN) A0HGQF.
